急性肾损伤电子预警系统:系统评价与荟萃分析
该研究为系统评价与荟萃分析,检索Embase、PubMed(2024年3月18日)和Cochrane图书馆(2024年3月20日),纳入13项研究、41 837例成人急性肾损伤患者,比较电子预警与标准护理或无预警。电子预警组死亡率RR 0.96(95%CI 0.89-1.03)、急性肾损伤分期进展RR 0.91(95%CI 0.84-0.99)、透析RR 1.16(95%CI 1.05-1.28)、肾脏恢复RR 1.13(95%CI 0.86-1.49)。临床实践方面,肾脏科会诊RR 1.45(95%CI 1.04-2.02)、急性肾损伤后非甾体抗炎药暴露RR 0.75(95%CI 0.59-0.95)、急性肾损伤记录RR 1.28(95%CI 1.04-1.58)。结论认为电子预警与死亡率降低无关,但改变临床实践并与急性肾损伤进展风险降低相关,需进一步研究整合早期标志物或预测模型以改善结局。
要点
- 电子预警组与标准护理相比,死亡率RR 0.96(95%CI 0.89-1.03),无显著差异。
- 电子预警组急性肾损伤分期进展风险降低(RR 0.91,95%CI 0.84-0.99)。
- 电子预警组透析风险升高(RR 1.16,95%CI 1.05-1.28),肾脏恢复无显著差异(RR 1.13,95%CI 0.86-1.49)。
- 电子预警组肾脏科会诊增加(RR 1.45,95%CI 1.04-2.02),急性肾损伤后非甾体抗炎药暴露减少(RR 0.75,95%CI 0.59-0.95)。
- 电子预警组急性肾损伤记录增加(RR 1.28,95%CI 1.04-1.58),住院时长(平均差-0.09天,95%CI -0.47至0.30)和费用(平均差655.26美元,95%CI -656.98至1967.5)无显著差异。
适用人群与场景
- 成人急性肾损伤患者,比较电子预警与标准护理或无预警。
- 排除重复队列、结局数据不足或无对照组的研究。
研究设计与关键结果
- 系统评价与荟萃分析纳入13项研究、41 837例患者(平均年龄范围60.5-79.0岁,女性29.3%-48.5%)。
- 电子预警组与标准护理相比:死亡率RR 0.96(95%CI 0.89-1.03),急性肾损伤分期进展RR 0.91(95%CI 0.84-0.99),透析RR 1.16(95%CI 1.05-1.28),肾脏恢复RR 1.13(95%CI 0.86-1.49)。
- 电子预警组肾脏科会诊RR 1.45(95%CI 1.04-2.02),急性肾损伤后非甾体抗炎药暴露RR 0.75(95%CI 0.59-0.95),急性肾损伤后ACEI/ARB暴露RR 0.91(95%CI 0.78-1.06),急性肾损伤记录RR 1.28(95%CI 1.04-1.58)。
- 住院时长平均差-0.09天(95%CI -0.47至0.30),费用平均差655.26美元(95%CI -656.98至1967.5),均无显著差异。
- 试验序贯分析证实电子预警增加肾脏科会诊、减少急性肾损伤后非甾体抗炎药暴露为真阳性结果,且与死亡率无关。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,遵循PRISMA指南,采用随机效应模型、预设亚组分析和试验序贯分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 电子预警与死亡率降低无关,不应以降低死亡率作为部署电子预警的主要预期。
- 电子预警可能增加肾脏科会诊(RR 1.45)、减少急性肾损伤后非甾体抗炎药暴露(RR 0.75)并增加急性肾损伤记录(RR 1.28)。
- 电子预警与急性肾损伤分期进展风险降低相关(RR 0.91),但与透析风险升高相关(RR 1.16),临床需结合患者具体情况解读。
- 作者认为需进一步研究确认这些结果,并整合早期急性肾损伤标志物或预测模型以改善结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The acute kidney injury (AKI) electronic alert (e-alert) system was hypothesized to improve the outcomes of AKI. However, its association with different patient outcomes and clinical practice patterns remains systematically unexplored.
OBJECTIVE: To assess the association of AKI e-alerts with patient outcomes (mortality, AKI progression, dialysis, and kidney recovery) and clinical practice patterns.
DATA SOURCES: A search of Embase and PubMed on March 18, 2024, and a search of the Cochrane Library on March 20, 2024, to identify all relevant studies. There were no limitations on language or article types.
STUDY SELECTION: Studies evaluating the specified outcomes in adult patients with AKI comparing AKI e-alerts with standard care or no e-alerts were included. Studies were excluded if they were duplicate cohorts, had insufficient outcome data, or had no control group.
DATA EXTRACTION AND SYNTHESIS: Two investigators independently extracted data and assessed bias. The systematic review and meta-analysis followed the PRISMA guidelines. Random-effects model meta-analysis, with predefined subgroup analysis and trial sequential analyses, were conducted.
MAIN OUTCOMES AND MEASURES: Primary outcomes included mortality, AKI progression, dialysis, and kidney recovery. Secondary outcomes were nephrologist consultations, post-AKI exposure to nonsteroidal anti-inflammatory drugs (NSAID), post-AKI angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker (ACEI/ARB) prescription, hospital length of stay, costs, and AKI documentation.
RESULTS: Thirteen unique studies with 41 837 unique patients were included (mean age range, 60.5-79.0 years]; 29.3%-48.5% female). The risk ratios (RRs) for the AKI e-alerts group compared with standard care were 0.96 for mortality (95% CI, 0.89-1.03), 0.91 for AKI stage progression (95% CI, 0.84-0.99), 1.16 for dialysis (95% CI, 1.05-1.28), and 1.13 for kidney recovery (95% CI, 0.86-1.49). The AKI e-alerts group had RRs of 1.45 (95% CI, 1.04-2.02) for nephrologist consultation, 0.75 (95% CI, 0.59-0.95) for post-AKI NSAID exposure. The pooled RR for post-AKI ACEI/ARB exposure in the AKI e-alerts group compared with the control group was 0.91 (95% CI, 0.78-1.06) and 1.28 (95% CI, 1.04-1.58) for AKI documentation. Use of AKI e-alerts was not associated with lower hospital length of stay (mean difference, -0.09 [95% CI, -0.47 to 0.30] days) or lower cost (mean difference, US $655.26 [95% CI, -$656.98 to $1967.5]) but was associated with greater AKI documentation (RR, 1.28 [95% CI, 1.04-1.58]). Trial sequential analysis confirmed true-positive results of AKI e-alerts on increased nephrologist consultations and reduced post-AKI NSAID exposure and its lack of association with mortality.
CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, AKI e-alerts were not associated with a lower risk for mortality but were associated with changes in clinical practices. They were associated with lower risk for AKI progression. Further research is needed to confirm these results and integrate early AKI markers or prediction models to improve outcomes.
参考来源
- Chen JJ, Lee TH, Chan MJ, et al. Electronic Alert Systems for Patients With Acute Kidney Injury: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024. PMID: 39190304. doi:10.1001/jamanetworkopen.2024.30401
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。